CMS transparency rules and AI could bring “Expedia-like” drug price comparisons for consumers, but payer compliance to transparency rules remains low.
News|Articles|April 1, 2002
ARB outperforms beta blocker for event prevention in hypertensives
For the first time, a beta blocker has been surpassed by another classof antihypertensive drug for the prevention of cardiovascular events inpatients with hypertension.
Advertisement
Advertisement
Related to this article
A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FAQ: State PBM reform in 2026—What's new since spring
2
New lean MASH mouse model could guide more targeted liver disease treatment in humans
3
Final GLOBE drug model projects much smaller savings while 2027 Part D premiums split
4
Tariffs on patented drugs now apply to all branded drugmakers
5